| Name | Title | Contact Details |
|---|
Kedrion Biopharma develops and produces plasma-derived therapies, making them available to meet patients` needs the world over. We collect and fractionate blood plasma for the development, production and distribution of plasma derivatives used in the treatment of patients suffering from rare and chronic conditions such as hemophilia and immune system deficiencies. A corporation is not a person, but a corporation is run by people and it affects people. And Kedrion`s business is people. The very nature of our enterprise is to help people live more full and healthy lives. This commitment extends to how we conduct our business, that is, in ways that are consistent with our mission: to build bridges that.benefit people. Long a major player in the plasma derivatives sector in Italy, as partner with the Italian Health System, Kedrion has now become an international participant in the industry with a market presence in about 100 countries. We have plants in Italy, Hungary and the United States and plasma collection centers in the U.S., Germany and Hungary. Kedrion looks forward to continued expansion and the wider sharing of its experience, know-how and technology to foster self-sufficiency of plasma-derived therapies worldwide and to bring healthier and less restricted lives to people suffering from rare disorders. Kedrion Biopharma produces wealth for investors, employees and for the local community, consistent with its own vision and values: responsibility, transparency, confidence in and respect for people. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion Biopharma builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.
Genesis Health Care Services is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Igentify® is a digital health company. We help clinicians, laboratories, and patients access, interpret, and use genetic information and education more effectively. Igentify developed the world`s first Digital Genetic Assistant, a software-based decision support platform. Our platform is capable of providing a fully scalable end-to-end genetic counseling solution in both clinical as well as non-clinical (direct-to-consumer) genetic testing set up. The platform is built for various genotyping technologies like microarray and next-generation sequencing (NGS). It can be customized to a broad spectrum of genetic and genomic tests offered by the test providers. Founded in Oct. 2016, Igentify`s team of globally renowned geneticists, highly experienced software developers, creative animators, and UX/UI designers, is redefining the protocols of traditional medicine. In Jan. 2019, Deloitte selected Igentify as one of the Israeli startups at the forefront of the Digital R&D Revolution.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
Queensland Health is the states largest healthcare provider, committed to ensuring all Queenslanders have access to a range of public healthcare services aimed at achieving good health and well being.